Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc. (ASBP) on February 6, 2026, covering events occurring on February 2, 2026. The filing details the creation and terms of a new class of equity securities, Series A Convertible Preferred Stock, pursuant to a Securities Purchase Agreement.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the structural terms of the new preferred stock issuance.
Material Changes
On February 2, 2026, the Company filed a Certificate of Designation with the Delaware Secretary of State to designate 25,000 shares of authorized and unissued preferred stock as Series A Convertible Preferred Stock. This action amends the Company's capital structure and introduces new senior securities with specific conversion and liquidation rights.
Terms, Risks, and Contingencies
- Conversion Terms: Shares are convertible at the holder's option into Common Stock at a price equal to 80% of the lowest closing price of the Common Stock over the five trading days prior to conversion. A floor price applies, set at 20% of the Nasdaq Minimum Price.
- Ownership Caps: Conversion is limited such that an investor cannot beneficially own more than 4.99% of the post-conversion Common Stock (adjustable up to 9.99% with notice). Aggregate issuance cannot exceed 19.99% without shareholder approval.
- Ranking and Liquidation: The Series A ranks senior to Common Stock and any junior securities. In a liquidation event, holders receive the greater of the conversion amount or the stated value plus accrued dividends before any distribution to junior stockholders.
- Price Protection: The conversion price is subject to downward adjustment if the Company issues securities at a price lower than the current conversion price (anti-dilution protection).
- Participation Rights: Holders have the right to participate in up to 30% of any subsequent financing occurring within six months of issuance on the same terms.
- Dividends and Voting: The stock has no voting rights except as required by law. Dividends are payable only if Common Stock dividends are paid, calculated based on the conversion ratio.
Investor Verification Checklist
- Verify the total number of Series A shares issued and the aggregate stated value to assess immediate dilution potential.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific definitions of "Exempt Issuance" and "Subsequent Financing."
- Confirm the current trading price of ASBP Common Stock to calculate the effective conversion price and potential share issuance.
- Assess the Company's current cash position and capital needs, as the filing mentions risks associated with cash needs and market conditions.
- Monitor for any future filings regarding shareholder approval required if conversions exceed the 19.99% threshold.